-
1 Comment
Hainan Huluwa Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 15.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.1.
Based on the above factors, Hainan Huluwa Pharmaceutical Group Co., Ltd gets an overall score of 1/5.
| ISIN | CNE100004223 |
|---|---|
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector | Healthcare |
| CurrencyCode | CNY |
| Exchange | SHG |
| Target Price | None |
|---|---|
| Dividend Yield | 0.0% |
| Beta | 0.65 |
| PE Ratio | 98.35 |
| Market Cap | 7B |
Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other therapeutic in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicines. The company was founded in 2005 and is based in Haikou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 605199.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
